The official journal of
EUROPAD - European Opiate Addiction Treatment Association
WFTOD - World Federation for the Treatment of Opioid Dependence
Editor: Icro Maremmani, MD - Pisa, Italy, EU
Associate Editors:
Thomas Clausen, MD - Oslo, Norway
Pier Paolo Pani, MD - Cagliari, Italy, EU
Marta Torrens, MD - Barcelona, Spain, EU
Statistical Editor:
Mario Miccoli, PhD - Pisa, Italy, EU

HARCP Archives

Browse by volume Browse by article Published Ahead
of Print

Heroin Addiction and Related Clinical Problems: 2021, 23, N6 (pages: 41 - 50)

Different formulations of methadone and levomethadone in the management of Opioid Use Disorder.

Somaini L., Vecchio S., Salvatore D.F., Ercolini A., and Leonardi C.

Summary: Opioid Agonist Treatment (OAT) has been found to be effective in treating Opioid Use Disorder (OUD), and methadone is still the most used drug worldwide for this purpose. However serious consideration should be given to the modality of methadone delivery, as it influences not only treatment outcomes, but also the attitudes of policy makers and the community. Treatment systems, providing a correct management of different methadone and levomethadone formulations based on patients' characteristics, have an impact on phenomena such as misuse and diversion of OAT. Availability of methadone tablets in many European countries has increased therapeutic strategies for the management of OUD improving the treatment outcomes. Identifying the correct treatment regimens along with choosing the most suitable drug formulations, adapted to the individual needs of the patient, is critical to avoid misuse and diversion during OAT.


AU-CNS Associazione per lā€™Utilizzo delle Conoscenze Neuroscientifiche a fini Sociali
Association for the Application of Neuroscientific Knowledge to Social Aims
Via XX Settembre, 83 ā€“ 55045 PIETRASANTA (Lucca) - Italy
P. IVA 01681650469 ā€“ Codice Fiscale 94002580465 Reserved Area
Tel/Phone: 0584 - 790073 - Email: info@heroinaddictionrelatedclinicalproblems.org
Start of page